BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020)
BridgeBio Pharma recorded quarterly Non-Current Deferred Tax Liability of $1.1 million in Q4 2020.
BridgeBio Pharma's Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $1.1 million for Q4 2020.
- In Q4 2020, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the TTM figure through Dec 2020 stood at $1.1 million (changed N/A YoY), while the FY2020 annual figure was $1.1 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $1.1 million for Q4 2020 at BridgeBio Pharma.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2020 to a low of $1.1 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.10 Mn |
| Dec 31, 2020 | 1.10 Mn |